Rohtak News Magazine

Relapsing Refractory Multiple Myeloma Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain

 Breaking News
  • No posts were found

Relapsing Refractory Multiple Myeloma Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain

December 08
10:40 2022
Relapsing Refractory Multiple Myeloma Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain

DelveInsight’s, “Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2022” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Relapsed/Refractory Multiple Myeloma Pipeline Report

  • DelveInsight’s Relapsed/Refractory Multiple Myeloma Pipeline report depicts a robust space with 35+ active players working to develop 60+ pipeline therapies for Relapsed/Refractory Multiple Myeloma.
  • The leading Relapsed/Refractory Multiple Myeloma Companies are working include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, and others.
  • Promising Relapsed/Refractory Multiple Myeloma Pipeline therapies such as Autologous BCMA CAR-T cells and CD19 CAR-T cells, AMG 701, ABBV-453, ABBV-383, Dexamethasone, ABT-199, Ixazomib, Pomalidomide, and others.
  • The Relapsed/Refractory Multiple Myeloma Companies and academics are working to assess challenges and seek opportunities that could influence Relapsed/Refractory Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed/Refractory Multiple Myeloma.

 

Recent Developmental Activities in the Relapsed/Refractory Multiple Myeloma Pipeline

  • NEXI-002 is an endogenous (non-genetically engineered) cellular therapy and includes populations of primed antigen specific CD8+ cells directed at five specific multiple myeloma antigen targets.  Generating T cells against multiple tumor targets minimizes the potential for tumor escape.  In addition, NEXI-002 contains T cell subtypes that are predominantly memory phenotypes, with the majority being characterized as stem cell memory and central memory T cells.  T cell products that contain high proportions of memory cells, particularly central memory and stem cell memory, have been associated with potent anti-tumor activity, long-term T cell persistence and durable anti-tumor response. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Multiple Myeloma.
  • Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.
  • ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Multiple Myeloma.

 

Get an overview of the Relapsed/Refractory Multiple Myeloma Clinical Trials @ Relapsed/Refractory Multiple Myeloma Pipeline Outlook Report

 

 

Relapsed/Refractory Multiple Myeloma Overview

Relapsed/refractory MM (RRMM) is defined as a disease which becomes non-responsive or progressive on therapy or within 60 days of the last treatment in patients who had achieved a minimal response (MR) or better on prior therapy. The approach to the patient with relapsed or relapsed/refractory multiple myeloma (RRMM) requires a careful evaluation of the results of previous treatments, the toxicities associated with them and an assessment of prognostic factors. Since the majority of patients will have received prior therapy with drug combinations including a proteasome inhibitor and/or an immunomodulatory drug (IMiD), it is the physician’s task to choose the right moment for the start of therapy and define with the patient which goals need to be achieved. The choice of regimen is usually based on prior responsiveness, drugs already received, prior adverse effects, the condition of the patient and expected effectiveness and tolerability. Many double and triple drug combinations are available. The aim of relapse treatment is to relieve disease symptoms and/or to prevent the development of CRAB symptoms.

 

Relapsed/Refractory Multiple Myeloma Pipeline Report

In the Relapsed/Refractory Multiple Myeloma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed/Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Relapsed/Refractory Multiple Myeloma Pipeline Therapeutics Assessment

 There are approx. 60+ key companies which are developing the therapies for Relapsed/Refractory Multiple Myeloma. The companies which have their Relapsed/Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase I/II include, NexImmune.

 

Relapsed/Refractory Multiple Myeloma Emerging Drugs Profile

  • ABBV 453: AbbVie
  • AMG-701: Amgen
  • NEXI 002: NexImmune

 

Request a sample and discover the recent advances in Relapsed/Refractory Multiple Myeloma Treatment Drugs @ Relapsed/Refractory Multiple Myeloma Ongoing Clinical Trials Analysis

 

Scope of the Relapsed/Refractory Multiple Myeloma Pipeline Insight Report

  • Coverage- Global
  • Relapsed/Refractory Multiple Myeloma Companies are working include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, and others.
  • Relapsed/Refractory Multiple Myeloma Pipeline therapies such as Autologous BCMA CAR-T cells and CD19 CAR-T cells, AMG 701, ABBV-453, ABBV-383, Dexamethasone, ABT-199, Ixazomib, Pomalidomide, and others
  • Relapsed/Refractory Multiple Myeloma Emerging Therapies, Unmet Needs, Analyst Views

 

Table of Content

  1. Introduction
  2. Relapsed/Refractory Multiple Myeloma Executive Summary
  3. Relapsed/Refractory Multiple Myeloma: Overview
  4. Relapsed/Refractory Multiple Myeloma Pipeline Therapeutics
  5. Relapsed/Refractory Multiple Myeloma Therapeutic Assessment
  6. Relapsed/Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. NEXI 002: NexImmune
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ABBV 453: AbbVie
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Relapsed/Refractory Multiple Myeloma Key Companies
  21. Relapsed/Refractory Multiple Myeloma Key Products
  22. Relapsed/Refractory Multiple Myeloma- Unmet Needs
  23. Relapsed/Refractory Multiple Myeloma- Market Drivers and Barriers
  24. Relapsed/Refractory Multiple Myeloma- Future Perspectives and Conclusion
  25. Relapsed/Refractory Multiple Myeloma Analyst Views
  26. Relapsed/Refractory Multiple Myeloma Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Relapsed/Refractory Multiple Myeloma drugs?
  • How many Relapsed/Refractory Multiple Myeloma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed/Refractory Multiple Myeloma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed/Refractory Multiple Myeloma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Relapsed/Refractory Multiple Myeloma and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Relapsed/Refractory Multiple Myeloma Pipeline therapeutics, reach out to Relapsed/Refractory Multiple Myeloma Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles